Login Register Cart 0
Generic placeholder image

Current Radiopharmaceuticals

Editor-in-Chief

ISSN (Print): 1874-4710
ISSN (Online): 1874-4729

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

90Y-DOTA-Nimotuzumab: Synthesis of a Promising β− Radiopharmaceutical

Author(s): Teresa Scotognella*, Daria Maccora, Isabella Bruno, Marco Chinol, Massimo Castagnola, Francesco Collamati, Carlo Mancini-Terraciano, Silvio Morganti, Valerio Bocci, Elena Solfaroli Camillocci, Dante Rotili, Antonella Cartoni, Ilaria Fratoddi, Federica Marini, Iole Venditti, Riccardo Faccini and Alessandro Giordano

Volume 15, Issue 1, 2022

Published on: 04 January, 2021

Page: [32 - 39] Pages: 8

DOI: 10.2174/1874471013999210104220031

Price: $65

Abstract

Background: Nimotuzumab is a humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody, nowadays used for tumour immunochemotherapy. This study aimed to label the conjugate DOTA-nimotuzumab with yttrium-90, in order to provide a β- emitting radioimmunoconjugate (90Y-DOTA-nimotuzumab) potentially useful to assess the feasibility of a new radio-guided surgery approach.

Methods: The synthesis of 90Y-DOTA-nimotuzumab was performed in two days. Nimotuzumab was conjugated with a 50-fold excess of DOTA and then labelled with 90Y3+. The 90Y-DOTA-nimotuzumab preparation was optimized considering several parameters such as pH, temperature and reaction volume. Moreover, the 90Y-DOTA-nimotuzumab stability was evaluated in human plasma.

Results: The radioimmunoconjugate 90Y-DOTA-nimotuzumab was obtained with a radiochemical purity greater than 96%, and showed a good stability at 20°C as well as at 37°C in human plasma.

Conclusions: The optimized conditions for a mild and easy preparation of 90Y-DOTA-nimotuzumab joined to a promising stability under physiological conditions suggest to propose this radioimmunoconjugate as a potential diagnostic radiopharmaceutical for β- radio-guided surgery.

Keywords: 90Y-DOTA-nimotuzumab, radio-guided surgery, molecular probe technique, radiopharmaceutical, monoclonal antibody, immunochemotherapy.

« Previous Next »
Graphical Abstract

[1]
Mariani, G.; Giuliano, A.E.; Strauss, H.W. Radioguided Surgery: A Comprehensive Team Approach; Springer: New York, NY, 2006.
[2]
Collamati, F.; Bellini, F.; Bocci, V.; De Lucia, E.; Ferri, V.; Fioroni, F.; Grassi, E.; Iori, M.; Marafini, M.; Morganti, S.; Paramatti, R.; Patera, V.; Recchia, L.; Russomando, A.; Sarti, A.; Sciubba, A.; Senzacqua, M.; Solfaroli Camillocci, E.; Versari, A.; Voena, C.; Faccini, R. Time evolution of DOTATOC uptake in neuroendocrine tumors in view of a possible application of radioguided surgery with β− decay. J. Nucl. Med., 2015, 56(10), 1501-1506.
[http://dx.doi.org/10.2967/jnumed.115.160481] [PMID: 26338895]
[3]
Suárez, J.P.; Domínguez, M.L.; de Santos, F.J.; González, J.M.; Fernández, N.; Enciso, F.J. Radioguided surgery in primary hyperparathyroidism: Results and correlation with intraoperative histopathologic diagnosis. Acta Otorrinolaringol. Esp., 2018, 69(2), 86-94.
[http://dx.doi.org/10.1016/j.otorri.2017.04.005] [PMID: 28807325]
[4]
Jangjoo, A.; Sadeghi, R.; Mousavi, Z.; Mohebbi, M.; Khaje, M.; Asadi, M. Minimally invasive radioguided parathyroid surgery using low-dose Tc-99m-MIBI - comparison with standard high dose. Endokrynol. Pol., 2017, 68(4), 398-401.
[http://dx.doi.org/10.5603/EP.a2017.0031] [PMID: 28553700]
[5]
Tiernan, J.P.; Ansari, I.; Hirst, N.A.; Millner, P.A.; Hughes, T.A.; Jayne, D.G. Intra-operative tumour detection and staging in colorectal cancer surgery. Colorectal Dis., 2012, 14(9), e510-e520.
[http://dx.doi.org/10.1111/j.1463-1318.2012.03078.x] [PMID: 22564278]
[6]
De Cicco, C.; Cremonesi, M.; Luini, A.; Bartolomei, M.; Grana, C.; Prisco, G.; Galimberti, V.; Calza, P.; Viale, G.; Veronesi, U.; Paganelli, G. Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer. J. Nucl. Med., 1998, 39(12), 2080-2084.
[PMID: 9867145]
[7]
Manca, G.; Romanini, A.; Pellegrino, D.; Borsò, E.; Rondini, M.; Orlandini, C.; Zucchi, V.; Pasqualetti, F.; Mariani, G. Optimal detection of sentinel lymph node metastases by intraoperative radioactive threshold and molecular analysis in patients with melanoma. J. Nucl. Med., 2008, 49(11), 1769-1775.
[http://dx.doi.org/10.2967/jnumed.108.055350] [PMID: 18927334]
[8]
Gulec, S.A.; Baum, R. Radioguided surgery in neuroendocrine tumors using Ga-68-labeled somatostatin analogs. J. Surg. Oncol., 2007, 96, 309-315.
[http://dx.doi.org/10.1002/jso.20868] [PMID: 17726664]
[9]
Kaemmerer, D.; Prasad, V.; Daffner, W. Radio-guided surgery in neuroendocrine tumors. Clin. Nucl. Med., 2012, 37, 142-147.
[http://dx.doi.org/10.1097/RLU.0b013e3182291de8] [PMID: 22228336]
[10]
Mancini-Terracciano, C.; Donnarumma, R.; Bencivenga, G.; Bocci, V.; Cartoni, A.; Collamati, F.; Fratoddi, I.; Giordano, A.; Indovina, L.; Maccora, D.; Marafini, M.; Mirabelli, R.; Morganti, S.; Rotili, D.; Russomando, A.; Scotognella, T.; Solfaroli Camillocci, E.; Toppi, M.; Traini, G.; Venditti, I.; Faccini, R. Feasibility of beta-particle radioguided surgery for a variety of “nuclear medicine” radionuclides. Phys. Med., 2017, 43, 127-133.
[http://dx.doi.org/10.1016/j.ejmp.2017.10.012] [PMID: 29195555]
[11]
Faccini, R. Patent PCT/IT2014/000025,
[12]
Solfaroli Camillocci, E.; Baroni, G.; Bellini, F.; Bocci, V.; Collamati, F.; Cremonesi, M.; De Lucia, E.; Ferroli, P.; Fiore, S.; Grana, M.C.; Marafini, M.; Mattei, I.; Morganti, S.; Paganelli, G.; Patera, V.; Piersanti, L. L. Recchia L, Russomando A, Schiariti M, Sarti A, Sciubba A, Voena C, Faccini R. A novel radioguided surgery technique exploiting β− decays. Sci. Rep., 2014, 4(4401), 1-5.
[http://dx.doi.org/10.1038/srep04401]
[13]
Collamati, F.; Pepe, A.; Bellini, F.; Bocci, V.; Chiodi, G.; Cremonesi, M.; De Lucia, E.; Ferrari, M.E.; Frallicciardi, P.M.; Grana, C.M.; Marafini, M.; Mattei, I.; Morganti, S.; Patera, V.; Piersanti, L.; Recchia, L.; Russomando, A.; Sarti, A.; Sciubba, A.; Senzacqua, M.; Solfaroli Camillocci, E.; Voena, C.; Pinci, D.; Faccini, R. Toward radioguided surgery with β- decays: uptake of a somatostatin analogue, DOTATOC, in meningioma and high-grade glioma. J. Nucl. Med., 2015, 56(1), 3-8.
[http://dx.doi.org/10.2967/jnumed.114.145995] [PMID: 25500828]
[14]
Venditti, I.; Cartoni, A.; Fontana, L.; Testa, G.; Scaramuzzo, F.A.; Faccini, R.; Mancini Terracciano, C.; Solfaroli Camillocci, E.; Morganti, S.; Giordano, A.; Scotognella, T.; Rotili, D.; Dini, V.; Marini, V.; Fratoddi, I.Y. 3+ embedded in polymeric nanoparticles: morphology, dimension and stability of composite colloidal system. Colloids Surf. A Physicochem. Eng. Asp., 2017, 532(5), 125-131.
[http://dx.doi.org/10.1016/j.colsurfa.2017.05.082]
[15]
Reddy, B.K.M.; Lokesh, V.; Vidyasagar, M.S.; Shenoy, K.; Babu, K.G.; Shenoy, A.; Naveen, T.; Joseph, B.; Bonanthaya, R.; Nanjundappa, ; Bapsy, P.P.; Loknatha, ; Shetty, J.; Prasad, K.; Tanvir Pasha, C.R. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients. Oral Oncol., 2014, 50(5), 498-505.
[http://dx.doi.org/10.1016/j.oraloncology.2013.11.008] [PMID: 24613543]
[16]
Talavera, A.; Friemann, R.; Gómez-Puerta, S.; Martinez-Fleites, C.; Garrido, G.; Rabasa, A.; López-Requena, A.; Pupo, A.; Johansen, R.F.; Sánchez, O.; Krengel, U.; Moreno, E. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res., 2009, 69(14), 5851-5859.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-4518] [PMID: 19584289]
[17]
Vera, D.R.; Eigner, S.; Beran, M.; Henke, K.E.; Laznickova, A.; Laznicek, M.; Melichar, F.; Chinol, M. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors. Cancer Biother. Radiopharm., 2011, 26(3), 287-297.
[http://dx.doi.org/10.1089/cbr.2010.0916] [PMID: 21711096]
[18]
Martinez, A.L.M.; Castillo, A.X.; Caldaza Falcon, V.N.; Perez- Malo Cruz, M.; Montana, R.L.; Barrabi, M.Z.; Gonzalez, I.H.; Perez, M.L.; Valdivia, A.A. Development of 90Y-DOTA-nimotuzumab Fab Fragment for radioimmunotherapy. J. Radioanal. Nucl. Chem., 2014, 302, 49-56.
[http://dx.doi.org/10.1007/s10967-014-3402-9]
[19]
Martelli, C.; Marzano, V.; Marini, F.; Scotognella, T.; Fratoddi, I.; Venditti, I.; Rotili, D.; Solfaroli-Camillocci, E.; Collamati, F.; Mancini-Terracciano, C.; Morganti, S.; Maccora, D.; Faccini, R.; Cartoni, A.; Giordano, A.; Castagnola, M. Mass spectrometry characterization of DOTA-Nimotuzumab conjugate as precursor of an innovative β- tracer suitable in radio-guided surgery. J. Pharm. Biomed. Anal., 2018, 156, 8-15.
[http://dx.doi.org/10.1016/j.jpba.2018.03.018] [PMID: 29704772]
[20]
Beckford Vera, D.R.; Eigner, S.; Eigner Henke, K.; Leyva Montaña, R.; Melichar, F.; Beran, M. (177)Lu/ (90)Y intermediate-affinity monoclonal antibodies targeting EGFR and HER2/c-neu: preparation and preclinical evaluation. Recent Results Cancer Res., 2013, 194, 301-317.
[http://dx.doi.org/10.1007/978-3-642-27994-2_16] [PMID: 22918766]
[21]
Alvarez, D.O.; Leyva Montana, R.; Samora Barrabi, M.; Hernandez, I.; Alonso, L.M. Modification of hR3 with DOTA-NHS. Labeling with 90Y and biodistribution. Nucleus, 2011, (49), 26-32.
[22]
Calzada, V.; Zhang, X.; Fernandez, M.; Diaz-Miqueli, A.; Iznaga-Escobar, N.; Deutscher, S.L.; Balter, H.; Quinn, T.P.; Cabral, P. A potencial theranostic agent for EGF-R expression tumors: (177)Lu-DOTA-nimotuzumab. Curr. Radiopharm., 2012, 5(4), 318-324.
[http://dx.doi.org/10.2174/1874471011205040318] [PMID: 22280117]
[23]
Vera, D.R.; Eigner, S.; Henke, K.E.; Lebeda, O.; Melichar, F.; Beran, M. Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors. Nucl. Med. Biol., 2012, 39(1), 3-13.
[http://dx.doi.org/10.1016/j.nucmedbio.2011.07.001] [PMID: 21958849]
[24]
Pandey, U; Kameswaran, M; Gamre, N; Dash, A. Preparation of 177Lu-labeled Nimotuzumab for radioimmunotherapy of EGFR- positive cancers: comparison of DOTA and CHX-A-DTPA as bifunctional chelating. J Label Compd Radiopharm, 2019, 1-8.
[25]
Martalena, R.; Hidayat, B.; Rustendi, C.T.; Subur, M.; Ardiyatno, C.N.; Aguswarini, S.; Humani, T.S.; Ritawidya, R.; Mutalib, A.; Masjhur, J.S. In vitro and n vivo testing of 177Lu_DOTA_Nimotuzumab, a potential radioimmunoptherapeutical agent of cancers. ITB J Sci, 2012, 44(4), 333-345.
[http://dx.doi.org/10.5614/itbj.sci.2012.44.4.4]
[26]
Barta, P.; Laznickova, A.; Laznicek, M.; Vera, D.R.; Beran, M. Preclinical evaluation of radiolabelled nimotuzumab, a promising monoclonal antibody targeting the epidermal growth factor receptor. J. Labelled Comp. Radiopharm., 2013, 56(5), 280-288.
[http://dx.doi.org/10.1002/jlcr.2988] [PMID: 24285372]

Rights & Permissions Print Cite
Article Metrics
27
1
© 2024 Bentham Science Publishers | Privacy Policy